Imricor Medical Systems, Inc.
CHIA:IMR Stock Report
Imricor Medical Systems Dividends and Buybacks
Dividend criteria checks 0/6 Imricor Medical Systems does not have a record of paying a dividend.
Key information Total Shareholder Yield -10.2% Future Dividend Yield 0% Dividend Growth n/a Next dividend pay date n/a Ex dividend date n/a Dividend per share n/a Payout ratio n/a
Recent dividend and buyback updates
Show all updates
Imricor Medical Systems, Inc. to Report First Half, 2024 Results on Aug 28, 2024 Aug 09
New major risk - Revenue and earnings growth Aug 08
New major risk - Shareholder dilution Jul 28
New major risk - Revenue and earnings growth Jul 02
Independent Non-Executive Director recently bought AU$73k worth of stock May 09
Imricor Medical Systems, Inc. to Report Q1, 2024 Results on Apr 30, 2024 Apr 23
Imricor Medical Systems, Inc., Annual General Meeting, May 15, 2024 Apr 09 Imricor Medical Systems, Inc. has completed a Follow-on Equity Offering in the amount of AUD 15.135297 million. Apr 02
Insufficient new directors Apr 01
New major risk - Revenue and earnings growth Mar 04
Full year 2023 earnings released: US$0.14 loss per share (vs US$0.12 loss in FY 2022) Mar 01
Imricor Medical Systems, Inc. to Report Fiscal Year 2023 Results on Feb 29, 2024 Feb 27
New major risk - Revenue and earnings growth Feb 12 Imricor Medical Systems, Inc. has filed a Follow-on Equity Offering in the amount of AUD 15 million. Feb 02
First half 2023 earnings released: US$0.061 loss per share (vs US$0.068 loss in 1H 2022) Aug 25
New major risk - Revenue and earnings growth Aug 25 Imricor Medical Systems, Inc. announced that it has received AUD 2.861607 million in funding Aug 17
Imricor Medical Systems, Inc. to Report First Half, 2023 Results on Aug 23, 2023 Aug 15 Imricor Medical Systems, Inc. announced that it has received AUD 1.457143 million in funding Jul 18
New minor risk - Share price stability Jun 14
Key Executive recently bought AU$195k worth of stock Mar 14
Full year 2022 earnings released Feb 24
Imricor Medical Systems, Inc. to Report Fiscal Year 2022 Results on Feb 22, 2023 Feb 08
Imricor Medical Systems, Inc. Receives IDE Approval from US FDA Jan 24
Forecast to breakeven in 2025 Dec 31
Imricor Medical Systems, Inc. Receives the First of Two Required Approvals to Commence the Vision-MR Ablation of VT or VISABL-VT Clinical Trial Dec 16 Imricor Medical Systems, Inc. announced that it expects to receive $5 million in funding from KAHR Foundation Dec 13
President recently bought AU$76k worth of stock Nov 16
President recently bought AU$76k worth of stock Nov 12
Imricor Medical Systems, Inc. to Report Q3, 2022 Results on Oct 27, 2022 Oct 24
Imricor Medical Systems, Inc. Submits Application for Approval to Commence A Real-Time iCMR-Guided Ventricular Tachycardia (VT) Ablation Clinical Trial Sep 19 Imricor Medical Systems, Inc. announced that it has received AUD 2.947049 million in funding Sep 15
First half 2022 earnings released: US$0.068 loss per share (vs US$0.079 loss in 1H 2021) Sep 02
Imricor Medical Systems, Inc. to Report First Half, 2022 Results on Aug 25, 2022 Aug 17
Imricor Medical Systems, Inc. to Report Q4, 2022 Results on Jul 28, 2022 Jul 19
Imricor Medical Systems, Inc. Completes its Preclinical Work to Support Submission for Approval to Initiate VT Clinical Trial in Europe Jun 29
Imricor Medical Systems, Inc., Annual General Meeting, May 03, 2022 Apr 08
Full year 2021 earnings: EPS in line with expectations, revenues disappoint Feb 26
Imricor Medical Systems, Inc. Announces Executive Changes Feb 11
Imricor Medical Systems, Inc. to Report Fiscal Year 2021 Results on Feb 24, 2022 Jan 28
Imricor Medical Systems, Inc. Files Application for an Investigational Device Exemption from US Food and Drug Administration Nov 24
First half 2021 earnings released: US$0.079 loss per share (vs US$0.056 loss in 1H 2020) Aug 28
No longer forecast to breakeven Jul 31
Non-Executive Director has left the company Mar 04
Imricor Medical Systems, Inc. Announces Board Changes Mar 04
Full year 2020 earnings released: US$0.11 loss per share (vs US$0.22 loss in FY 2019) Feb 26
Revenue beats expectations Feb 26
New 90-day low: AU$2.17 Feb 18
Imricor Medical Systems, Inc. to Report Fiscal Year 2020 Results on Feb 25, 2021 Feb 01
Imricor Medical Systems, Inc. Appoints Gregg Stenzel as COO Dec 30
Imricor Signs Supply and Sales Agreement with Osypka Dec 11
Imricor Medical Systems, Inc. Signs New Purchase Agreement Nov 27
Imricor Medical Systems, Inc. (ASX:IMR) signed an agreement to acquire Schleswig-Holstein University Medical Centre in Germany. Oct 29
Imricor Medical Systems, Inc. to Commence Clinical Procedures After Receiving Ethics Committee Approval to Use Isuite Software Oct 12
Imricor Awards National Institutes of Health Contract Oct 05
Imricor Medical Systems, Inc. Signs Purchase Agreement with MUMC Sep 30
Leipzig Heart Centre Signs Purchase Agreement with Imricor Medical Systems Sep 21
Earnings released Aug 25
Imricor Medical Systems, Inc. to Report Fiscal Year 2020 Results on Aug 25, 2020 Aug 04
Imricor Medical Systems, Inc. to Report Q2, 2020 Results on Jul 29, 2020 Jul 21
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if IMR's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if IMR's dividend payments have been increasing.
Dividend Yield vs Market Imricor Medical Systems Dividend Yield vs Market
How does IMR dividend yield compare to the market? Segment Dividend Yield Company (IMR) n/a Market Bottom 25% (AU) 2.6% Market Top 25% (AU) 6.1% Industry Average (Medical Equipment) 1.5% Analyst forecast (IMR) (up to 3 years) 0%
Notable Dividend: Unable to evaluate IMR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate IMR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate IMR's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as IMR has not reported any payouts.
Discover strong dividend paying companies Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"control","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}